組織金屬蛋白酶抑制因子2(TIMP2)活性蛋白
Active Tissue Inhibitors Of Metalloproteinase 2 (TIMP2)
CSC-21K; TIMP Metallopeptidase Inhibitor 2
- 編號APA128Hu03
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 80%
- 等電點6.5
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1675 ¥ 4188 ¥ 8376 ¥ 25128 ¥ 62820
- 欲了解實際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
活性實驗
Tissue inhibitors of metalloproteinases or TIMPs are a family of proteins that regulate the activation and proteolytic activity of the zinc enzymes known as matrix metalloproteinases (MMPs). There are four members of the family, TIMP-1, TIMP-2, TIMP-3, and TIMP-4. TIMP-2 is a non N-glycosylated protein with a molecular mass of 22 kDa produced by a wide range of cell types, which inhibits MMPs non-covalently by the formation of binary complexes. TIMP-2 also has erythroidpotentiating and cell growth promoting activities. The activity of recombinant human TIMP2 was measured by its ability to inhibit rhMMP2 cleavage of a fluorogenic peptide substrate MCA-Pro-Leu-Gly-Leu-DPA-Ala-Arg-NH2 in the assay buffer 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% (w/v) Brij-35, pH 7.5. rhMMP2 was diluted to 100 ug/ml and activated with 1 mM APMA at 37 °C for 1 hour and rhTIMP2 (MW: 51.75 KD) was diluted to different concentrations with the assay buffer. Mix 8 μl of rhTIMP2 curve dilutions, 12.8 μl of activated rhMMP-2, and 59.2 μl of assay buffer, including a control containing assay buffer and the diluted rhMMP-2 and incubate the reactions for 2 hours at 37 °C. Loading 50?μl of the incubated mixtures which were diluted five-fold in assay buffer into empty wells of a plate, and start the reaction by adding 50?μl of 20?μM substrate. Include a substrate blank containing 50?μl of assay buffer and 50?μl of 20?μM substrate. Then read at excitiation and emission wavelengths of 320 nm and 405 nm, respectively, in kinetic mode for 5 minutes. The result was shown in Figure 1 and it was obvious that recombinant human TIMP2 significantly decreased rhMMP2 activity. The inhibition IC50 was <20 nM.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
APA128Hu02 | 組織金屬蛋白酶抑制因子2(TIMP2)活性蛋白 | Cell?culture;?Activity?Assays. |
APA128Hu01 | 組織金屬蛋白酶抑制因子2(TIMP2)活性蛋白 | Cell?culture;?Activity?Assays. |
EPA128Hu61 | 組織金屬蛋白酶抑制因子2(TIMP2)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA128Hu61 | 組織金屬蛋白酶抑制因子2(TIMP2)活性蛋白 | Cell?culture;?Activity?Assays. |
RPA128Hu02 | 組織金屬蛋白酶抑制因子2(TIMP2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA128Hu03 | 組織金屬蛋白酶抑制因子2(TIMP2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA128Hu03 | 組織金屬蛋白酶抑制因子2(TIMP2)活性蛋白 | Cell?culture;?Activity?Assays. |
RPA128Hu01 | 組織金屬蛋白酶抑制因子2(TIMP2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA128Hu01 | 組織金屬蛋白酶抑制因子2(TIMP2)多克隆抗體 | WB; IHC; ICC; IP. |
PAA128Hu06 | 組織金屬蛋白酶抑制因子2(TIMP2)多克隆抗體 | WB; IHC; ICC; IP. |
LAA128Hu71 | 組織金屬蛋白酶抑制因子2(TIMP2)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
MAA128Hu22 | 組織金屬蛋白酶抑制因子2(TIMP2)單克隆抗體 | WB; IHC; ICC; IP. |
SEA128Hu | 組織金屬蛋白酶抑制因子2(TIMP2)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA128Hu | 組織金屬蛋白酶抑制因子2(TIMP2)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
The Journal of Nutrition | Oral Administration of 3,3′-Diindolylmethane Inhibits Lung Metastasis of 4T1 Murine Mammary Carcinoma Cells in BALB/c Mice [Nutrition&Metabolism: source] |
Breast Cancer Research and Treatment | Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice [SpringerLink: f3w831267267p277] |
Moleculer Vision | Bone morphogenetic protein-2: a potential regulator in scleral remodeling [PubMed: PMC2605409] |
Experimental & Translational Stroke Medicine | Early outcome and blood-brain barrier integrity after co-administered thrombolysis and hyperbaric oxygenation in experimental stroke [PubMed: 21679435] |
PLoS ONE | A Combinatorial Relative Mass Value Evaluation of Endogenous Bioactive Proteins in Three-Dimensional Cultured Nucleus Pulposus Cells of Herniated Intervertebral Discs: Identification of Potential Target Proteins for Gene Therapeutic Approaches [Plosone: Source] |
Polski Przeglad Chirurgiczny | Concentration of gelatinases and their tissue inhibitors in pancreatic inflammatory and neoplastic tumors and their influence on the early postoperative course [Pubmed: 23585206] |
Thromb Haemost. | Analysis of the expression of nine secreted matrix metalloproteinases and their endogenous inhibitors in the brain of mice subjected to ischaemic stroke [Pubmed:24671655] |
Pediatric Anesthesia? | Impact of 6% hydroxyethyl starch 130/0.42 and 5% gelatin on renal function in a pediatric animal model [Pubmed:24916275] |
PLOS ONE | The Complementary Effects of Atorvastatin and Exercise Treatment on the Composition and Stability of the Atherosclerotic Plaques in ApoE Knockout Mice [Pubmed:25264981] |
Brain, Behavior, and Immunity | Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model [Pubmed:25266150] |
Mediators of Inflammation | Metalloproteinases and Their Tissue Inhibitors in Comparison between Different Chronic Pneumopathies in the Horse [Journals: Mi] |
Brain, Behavior, and Immunity | Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model [PubMed: 25266150] |
physiological research | The skin remodeling in type 1 diabetes and insulin resistance animal models [PubMed: 26047379] |
Physiol Res | The skin remodeling in type 1 diabetes and insulin resistance animal models. [PubMed: 26047379] |
J Periodontal Implant Sci | Assessment of MMP-1, MMP-8 and TIMP-2 in experimental periodontitis treated with kaempferol [pmc:PMC4848383] |
Int Wound J. | From varices to venous ulceration: the story of chronic venous disease described by metalloproteinases. [Pubmed:26991748] |
BMC Veterinary Research | Metalloproteinases?and their?inhibitors?are?influenced?by?inhalative?glucocorticoid?therapy?incombination?with?environmental?dust?reduction?in?equine?recurrent airway obstruction. [pubmed:27938355] |
Journal of Applied Animal Research | Hypoxia enhances secretion of matrix metalloproteinases in bovine dermal fibroblasts:an in vitro approach to bovine digital dermatitis [10.108:09712119.2017.1335208] |
Cellular Physiology and Biochemistry | The MiR-495/Annexin A3/P53 Axis Inhibits the Invasion and EMT of Colorectal Cancer Cells [pubmed:29224019] |
International Wound Journal | From varices to venous ulceration: the story of chronic venous disease described by metalloproteinases [pubmed:26991748] |
Journal of Applied Animal Research? | Hypoxia enhances secretion of matrix metalloproteinases in bovine dermal fibroblasts: an approach to bovine digital dermatitis [10.1080:09712119.2017.1335208] |
Mediators of Inflammation | Metalloproteinases and their Inhibitors under the Course of Immunostimulation by CPG-ODN and Specific Antigen Inhalation in Equine Asthma [] |
Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists | Correlation of Baseline Plasma and Inguinal Connective Tissue Metalloproteinases and Their Inhibitors With Late High-Pressure Endoleak After Endovascular?… [Pubmed: 31464166] |
Scientific Reports | Matrix metallopeptidase expression and modulation by transforming growth factor-β1 in equine endometrosis [Pubmed: 31980722] |
MEDIATORS OF INFLAMMATION | MMP-9 Concentration in Peritoneal Fluid Is a Valuable Biomarker Associated with Endotoxemia in Equine Colic [33488296] |
Calcium Binding Protein S100A16 Expedites Proliferation, Invasion and EMT Process in Gastric Cancer [34650982] |